The Insightful Corner Hub: The Ethics of Digital Twins in Clinical Trials: A Public Health Researcher’s Perspective

 

Introduction

Clinical trials are the foundation of evidence-based medicine. For decades, randomized controlled trials (RCTs) have served as the gold standard for determining whether new drugs, vaccines, or medical devices are safe and effective. However, the traditional clinical trial model is increasingly challenged by high costs, long timelines, participant recruitment barriers, and limited representation of diverse patient populations.

In recent years, the healthcare research ecosystem has begun shifting toward digitally enabled clinical research models, including decentralized clinical trials (DCTs) and the emerging concept of digital twins in medicine. These innovations aim to improve trial efficiency, enhance patient safety, and accelerate the development of therapeutic interventions.

Digital twins virtual representations of patients generated using artificial intelligence (AI), biomedical data, and computational modeling have the potential to transform clinical trials. By simulating how individuals or populations might respond to treatments, digital twins may reduce the need for large control groups, predict adverse outcomes earlier, and enable more personalized research designs.

Yet the integration of digital twins into clinical research raises important ethical questions. Public health researchers, regulators, and clinical investigators must consider issues such as patient autonomy, data privacy, algorithmic bias, scientific validity, and regulatory oversight.

From a public health perspective, the ethical evaluation of digital twin technologies must go beyond technical feasibility. It must ensure that innovation in clinical research aligns with principles of justice, transparency, accountability, and patient protection. While community awareness is vital, the future of disease surveillance lies in predictive modeling. I recently analyzed how Machine Learning is Redefining Post-Market Surveillance for 2026.

This article explores the ethical implications of digital twins in clinical trials, particularly within the broader transition toward decentralized clinical research. It also examines how regulatory authorities such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are addressing the governance of AI-driven clinical methodologies.

Understanding Digital Twins in Healthcare

Definition and Conceptual Framework

The concept of a digital twin originated in engineering and industrial design, where virtual replicas of physical systems are used to simulate performance and predict outcomes. In healthcare, a digital twin refers to a computational model that replicates the biological, physiological, and behavioral characteristics of a patient or patient population.

The creation of a high-fidelity Digital Twin relies on the same predictive architectures I recently explored in my analysis of Machine Learning in Pharmacoepidemiology. These models allow us to redefine post-market surveillance for the 2026 landscape.

Digital twins are constructed using large volumes of health data, including:

• Electronic health records (EHRs)
• Genomic data
• Imaging datasets
• Laboratory results
• Wearable device data
• Environmental exposure data

Artificial intelligence algorithms analyze these datasets to build models capable of simulating disease progression and treatment responses.

In clinical research, digital twins can serve several purposes:

• Simulating control groups
• Predicting patient responses to interventions
• Testing treatment scenarios before human exposure
• Identifying potential adverse drug reactions

While the technology is still evolving, its potential implications for clinical trial design are substantial.

The Rise of Decentralized Clinical Trials

Traditional Clinical Trial Limitations

Conventional clinical trials typically require participants to travel to centralized research sites for screening, treatment administration, and follow-up assessments. In a decentralized environment, the pharmacist's role in risk mitigation is paramount. This virtual oversight aligns with my Senior Pharmacist’s Protocol for Preventing Adverse Drug Reactions (ADRs), which emphasizes structured medication review as a safeguard against avoidable harm.

This model presents several barriers:

• Geographic accessibility limitations
• High operational costs
• Slow patient recruitment
• Underrepresentation of rural and minority populations
• Participant burden and dropouts

These challenges have contributed to rising clinical trial costs and delays in bringing new therapies to market.

What Are Decentralized Clinical Trials?

Decentralized clinical trials leverage digital health technologies to conduct research remotely. Key components of decentralized trials include:

• Telemedicine consultations
• Remote patient monitoring
• Digital informed consent systems
• Wearable health devices
• Home-based specimen collection

This approach enables participants to contribute data without frequent visits to clinical research centers.

Decentralized trials gained significant momentum during the COVID-19 pandemic, when physical distancing measures disrupted traditional clinical research operations.

Today, regulators and pharmaceutical companies increasingly recognize decentralized trial models as a viable approach to improving research efficiency and patient participation.

Digital Twins as Virtual Participants in Clinical Trials

Digital twins extend the concept of decentralized trials by introducing AI-generated virtual patients into research protocols.

Instead of recruiting large groups of human participants to serve as controls, researchers may use digital twins to simulate how similar patients would respond without receiving the experimental treatment.

Virtual Control Arms

In traditional randomized trials, participants are often assigned to control groups receiving placebo or standard therapy. Digital twin models can replicate the expected outcomes for these control patients using historical and real-world data.

This approach can:

• Reduce the number of participants exposed to placebo
• Increase statistical efficiency
• Accelerate trial timelines

However, the use of simulated participants introduces ethical and methodological considerations.

Infographic illustrating how AI-generated digital twins are transforming clinical trials while raising ethical concerns about data privacy, algorithmic bias, informed consent, and regulatory oversight from agencies such as the FDA and EMA.

Ethical Foundations of Clinical Research

The ethical evaluation of digital twin technologies must be grounded in established research ethics principles.

Three foundational frameworks guide ethical clinical research:

1. The Belmont Report principles
2. International Council for Harmonisation (ICH) Good Clinical Practice guidelines
3. Regulatory oversight from agencies such as the FDA and EMA

The Belmont Report emphasizes three ethical principles:

• Respect for persons
• Beneficence
• Justice

These principles remain central to evaluating new research methodologies involving artificial intelligence and digital health technologies.

Ethical Issue 1: Scientific Validity and Reliability

One of the most critical ethical concerns surrounding digital twins is the scientific validity of simulated patients.

Clinical trials must produce reliable evidence that can guide medical decision-making. If digital twin models are inaccurate or biased, they could compromise the integrity of research findings.

Model Transparency

AI models used to generate digital twins often rely on complex machine learning architectures that may lack interpretability. This raises questions about how researchers and regulators can evaluate the reliability of simulation outcomes.

Transparency in algorithm design and training data is therefore essential.

Validation Requirements

Regulatory authorities emphasize that digital twin models must undergo rigorous validation before being used in clinical trials.

Validation processes may include:

• External dataset testing
• Replication across diverse populations
• Comparison with real-world outcomes

Without robust validation, digital twins risk introducing systematic errors into clinical research.

Ethical Issue 2: Patient Data Privacy

Digital twin systems require extensive patient data to build accurate models. These datasets may include highly sensitive health information.

From a public health ethics perspective, protecting patient privacy is paramount.

Data Governance

Digital twin development must adhere to strict data governance standards, including:

• Secure data storage
• De-identification procedures
• Controlled data access

Researchers must also ensure compliance with regional data protection regulations such as the General Data Protection Regulation (GDPR) in Europe.

Consent for Data Use

Another ethical consideration involves the use of historical patient data to create digital twins.

Patients may not always be aware that their medical data could be used to develop simulation models for research purposes.

Ethically sound digital twin systems must incorporate transparent consent mechanisms that inform patients about potential secondary uses of their data.

Ethical Issue 3: Algorithmic Bias and Health Equity

Artificial intelligence systems learn from historical data. If these datasets contain demographic imbalances or structural biases, the resulting models may produce inequitable predictions.

In clinical research, algorithmic bias could lead to:

• Inaccurate predictions for minority populations
• Exclusion of underrepresented patient groups
• Reduced external validity of research findings

Public health researchers must ensure that digital twin models are trained using diverse datasets that reflect the heterogeneity of real-world populations.

This is particularly important for global health equity.

Ethical Issue 4: Informed Consent in AI-Driven Trials

Informed consent is a cornerstone of ethical clinical research.

The use of digital twins introduces new complexities into the consent process.

Participants must understand:

• How their data may be used to create simulation models
• Whether digital twins will influence trial design
• How AI-generated predictions may affect treatment allocation

Clear communication about the role of artificial intelligence in clinical research is essential to maintaining participant trust.

Ethical Issue 5: Accountability and Responsibility

Another key ethical challenge involves determining responsibility when AI-driven decisions influence clinical trial outcomes.

Questions arise such as:

• Who is accountable if a digital twin model produces inaccurate predictions?
• Should liability rest with software developers, trial sponsors, or investigators?

Establishing clear governance frameworks for AI-assisted research is necessary to ensure accountability.

Regulatory Perspectives

United States Regulatory Framework

The FDA has increasingly engaged with AI-driven healthcare technologies, including digital health software and clinical decision support tools.

The agency has released several guidance documents addressing artificial intelligence in healthcare, emphasizing principles such as:

• Transparency
• Algorithm validation
• Lifecycle monitoring

While digital twins are still an emerging technology, the FDA encourages developers to demonstrate robust evidence supporting model accuracy and clinical relevance.

European Regulatory Approach

The EMA also recognizes the growing role of AI in healthcare research.

European regulators emphasize:

• Ethical data use
• Patient safety
• Transparency in algorithm development

The European Union has also proposed the Artificial Intelligence Act, which classifies AI systems used in healthcare as high-risk technologies requiring strict oversight.

These regulatory frameworks aim to ensure that AI innovations in clinical trials do not compromise patient safety.

Potential Benefits of Digital Twins

Despite ethical concerns, digital twins offer several promising advantages.

Reduced Patient Risk

Digital simulations can help researchers identify potential safety issues before exposing human participants to experimental therapies.

Faster Drug Development

By reducing the need for large control groups, digital twins may accelerate clinical trial timelines.

Personalized Medicine

Digital twins may enable researchers to simulate treatment responses at the individual patient level, supporting precision medicine approaches.

Public Health Implications

From a public health perspective, digital twin technologies could reshape how clinical evidence is generated.

If implemented ethically, these technologies could:

• Expand access to clinical trials
• Improve representation of diverse populations
• Enhance pharmacovigilance
• Reduce research costs

However, the public health community must remain vigilant to ensure that innovation does not exacerbate health inequalities.

Future Directions

The future of digital twins in clinical trials will likely involve hybrid research models combining human participants with AI-generated simulations.

Advancements in several fields will influence this trajectory:

• Computational biology
• Biomedical data science
• Genomic medicine
• Digital health infrastructure

Collaborations between regulators, researchers, and technology developers will be essential for establishing ethical standards.

The Role of Public Health Researchers

Public health professionals have a crucial role in evaluating the societal impact of digital health technologies.

Their responsibilities include:

• Assessing population-level implications
• Identifying ethical risks
• Promoting equitable access to innovation
• Ensuring that research methods protect vulnerable populations

By integrating ethical analysis into technological development, public health researchers can guide responsible innovation.

FAQs

What are digital twins in clinical trials?

Digital twins in clinical trials are AI-generated virtual representations of patients that simulate biological, physiological, and behavioral characteristics to predict treatment responses and adverse outcomes.

How do digital twins improve decentralized clinical trials?

Digital twins allow virtual control groups, reduce the number of participants exposed to placebo, and enable remote monitoring, making decentralized trials faster, safer, and more efficient.

What are the main ethical concerns with digital twins?

Ethical concerns include patient data privacy, algorithmic bias, scientific validity, informed consent, accountability for AI decisions, and ensuring equitable representation in research.

How is patient privacy protected when using digital twins?

Privacy protection involves secure data storage, data de-identification, controlled access, and compliance with regulations like GDPR in Europe and HIPAA in the USA.

Can digital twins replace human participants entirely in trials?

Not currently. Digital twins complement human participants, especially for control groups or simulation studies. Full replacement is limited by the need for real-world validation and regulatory oversight.

How do FDA and EMA regulate the use of digital twins?

The FDA and EMA require validation of AI models, transparency in algorithm design, and adherence to ethical standards. AI-driven tools are classified as high-risk and must demonstrate reliability, patient safety, and clinical relevance.

What role do public health researchers play in digital twin implementation?

Public health researchers assess societal and population-level impacts, ensure ethical standards, promote equitable access, and evaluate potential health inequalities associated with AI-driven clinical research.

What are the benefits of using digital twins in clinical research?

Benefits include reduced patient risk, faster trial timelines, improved representation of diverse populations, enhanced pharmacovigilance, and enabling personalized medicine approaches.

Conclusion

Digital twins represent one of the most intriguing developments in modern clinical research. By creating AI-generated models of patients, researchers may be able to simulate treatment responses, accelerate drug development, and improve patient safety.

However, the ethical implications of this technology are profound.

Ensuring scientific validity, protecting patient privacy, preventing algorithmic bias, maintaining informed consent, and establishing clear accountability structures are all essential for responsible implementation.

Regulatory agencies such as the FDA and EMA are beginning to address these challenges through evolving guidance frameworks. Yet the ethical governance of digital twins will require ongoing collaboration across disciplines.

From a public health researcher's perspective, digital twin technology must ultimately serve the broader goals of medicine: improving health outcomes, protecting patient welfare, and advancing scientific knowledge in a fair and transparent manner.

The integration of artificial intelligence into clinical trials is not simply a technical innovation it represents a transformation in how medical evidence is generated. As this transformation unfolds, ethical oversight must remain central to ensuring that the future of clinical research benefits all populations.

About the Author

Joseph NZAYISENGA, B.Pharm, MPH, MSc | Scopus-Indexed Researcher | Senior Pharmacist & Epidemiologist 

Joseph NZAYISENGA, B.Pharm, MPH, MSc is a Rwandan-registered Senior Pharmacist and Epidemiologist specializing in the intersection of AI in Healthcare and Pharmacoepidemiology. A Scopus-indexed researcher and reviewer for Acta Scientific Pharmaceutical Sciences, he holds a Master of Public Health in Epidemiology and Disease Control and an MSc in Business Studies. His work focuses on advancing medication safety and ethical research standards through digital health innovation.